Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications
Condition: Venous Thromboembolism; covid19; Thrombosis
MeSH terms: COVID-19; Thrombosis; Thromboembolism; Venous Thromboembolism; Inflammation
Study type: Interventional

Summary: 
      The study is aimed at assessing the role of the activity of high-risk markers of thrombotic
      events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of
      thrombotic complications in patients with COVID -19.
    

Detailed description: 
      The study is aimed at assessing the role of the activity of high-risk markers for thrombotic
      events (monocytic chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1α
      (MIP1α), interferon-induced gamma protein-10 (IP-10), platelet apoptosis markers
      (phosphatedylserine, calreticulin) on the development of thrombotic complications in patients
      with COVID -19.

      The study will include 150 patients of similar age, gender, and ethnicity, and they will be
      divided into three groups: Group I: 50 patients with confirmed coronavirus infection without
      thrombotic complications; Group II: 50 patients with confirmed coronavirus infection with
      thrombotic complications confirmed by ultrasonography without the use of pharmacomechanical
      prophylaxis of VTE; Group III: 50 patients with confirmed coronavirus infection with
      ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities
      using pharmacomechanical prophylaxis of VTE
    

Intervention name(s): standard of care anticoagulation in absence of thrombotic complications; standard of care anticoagulation in presence of thrombotic complications; standard of care anticoagulation in combination with elastic compression
Intervention type(s): Other; Other; Other
Intervention description(s): Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE; Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE; Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Intervention model description: Open-label cohort longitudinal study
Masking: None (Open Label)
Primary purpose: Other
Keywords: venous thromboembolism; VTE; thrombotic events; coronavirus; COVID-19; hemostasis; platelet function